Cargando…

Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes

Autism Spectrum Disorder (ASD) is a set of heterogeneous neurodevelopmental conditions defined by impairments in social communication and restricted, repetitive behaviors, interests or activities. Only a minority of ASD cases are determined to have a definitive etiology and the pathogenesis of most...

Descripción completa

Detalles Bibliográficos
Autores principales: Abraham, Joseph R., Szoko, Nicholas, Barnard, John, Rubin, Robert A., Schlatzer, Daniela, Lundberg, Kathleen, Li, Xiaolin, Natowicz, Marvin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739414/
https://www.ncbi.nlm.nih.gov/pubmed/31511657
http://dx.doi.org/10.1038/s41598-019-49533-y
_version_ 1783450940414623744
author Abraham, Joseph R.
Szoko, Nicholas
Barnard, John
Rubin, Robert A.
Schlatzer, Daniela
Lundberg, Kathleen
Li, Xiaolin
Natowicz, Marvin R.
author_facet Abraham, Joseph R.
Szoko, Nicholas
Barnard, John
Rubin, Robert A.
Schlatzer, Daniela
Lundberg, Kathleen
Li, Xiaolin
Natowicz, Marvin R.
author_sort Abraham, Joseph R.
collection PubMed
description Autism Spectrum Disorder (ASD) is a set of heterogeneous neurodevelopmental conditions defined by impairments in social communication and restricted, repetitive behaviors, interests or activities. Only a minority of ASD cases are determined to have a definitive etiology and the pathogenesis of most ASD is poorly understood. We hypothesized that a global analysis of the proteomes of human ASD vs. control brain, heretofore not done, would provide important data with which to better understand the underlying neurobiology of autism. In this study, we characterized the proteomes of two brain regions, Brodmann area 19 (BA19) and posterior inferior cerebellum (CB), from carefully selected idiopathic ASD cases and matched controls using label-free HPLC-tandem mass spectrometry. The data revealed marked differences between ASD and control brain proteomes for both brain regions. Unlike earlier transcriptomic analyses using frontal and temporal cortex, however, our proteomic analysis did not support ASD attenuating regional gene expression differences. Bioinformatic analyses of the differentially expressed proteins between cases and controls highlighted canonical pathways involving glutamate receptor signaling and glutathione-mediated detoxification in both BA19 and CB; other pathways such as Sertoli cell signaling and fatty acid oxidation were specifically enriched in BA19 or CB, respectively. Network analysis of both regions of ASD brain showed up-regulation of multiple pre- and post-synaptic membrane or scaffolding proteins including glutamatergic ion channels and related proteins, up-regulation of proteins involved in intracellular calcium signaling, and down-regulation of neurofilament proteins, with DLG4 and MAPT as major hub proteins in BA19 and CB protein interaction networks, respectively. Upstream regulator analysis suggests neurodegeneration-associated proteins drive the differential protein expression for ASD in both BA19 and CB. Overall, the proteomic data provide support for shared dysregulated pathways and upstream regulators for two brain regions in human ASD brain, suggesting a common ASD pathophysiology that has distinctive regional expression.
format Online
Article
Text
id pubmed-6739414
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67394142019-09-22 Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes Abraham, Joseph R. Szoko, Nicholas Barnard, John Rubin, Robert A. Schlatzer, Daniela Lundberg, Kathleen Li, Xiaolin Natowicz, Marvin R. Sci Rep Article Autism Spectrum Disorder (ASD) is a set of heterogeneous neurodevelopmental conditions defined by impairments in social communication and restricted, repetitive behaviors, interests or activities. Only a minority of ASD cases are determined to have a definitive etiology and the pathogenesis of most ASD is poorly understood. We hypothesized that a global analysis of the proteomes of human ASD vs. control brain, heretofore not done, would provide important data with which to better understand the underlying neurobiology of autism. In this study, we characterized the proteomes of two brain regions, Brodmann area 19 (BA19) and posterior inferior cerebellum (CB), from carefully selected idiopathic ASD cases and matched controls using label-free HPLC-tandem mass spectrometry. The data revealed marked differences between ASD and control brain proteomes for both brain regions. Unlike earlier transcriptomic analyses using frontal and temporal cortex, however, our proteomic analysis did not support ASD attenuating regional gene expression differences. Bioinformatic analyses of the differentially expressed proteins between cases and controls highlighted canonical pathways involving glutamate receptor signaling and glutathione-mediated detoxification in both BA19 and CB; other pathways such as Sertoli cell signaling and fatty acid oxidation were specifically enriched in BA19 or CB, respectively. Network analysis of both regions of ASD brain showed up-regulation of multiple pre- and post-synaptic membrane or scaffolding proteins including glutamatergic ion channels and related proteins, up-regulation of proteins involved in intracellular calcium signaling, and down-regulation of neurofilament proteins, with DLG4 and MAPT as major hub proteins in BA19 and CB protein interaction networks, respectively. Upstream regulator analysis suggests neurodegeneration-associated proteins drive the differential protein expression for ASD in both BA19 and CB. Overall, the proteomic data provide support for shared dysregulated pathways and upstream regulators for two brain regions in human ASD brain, suggesting a common ASD pathophysiology that has distinctive regional expression. Nature Publishing Group UK 2019-09-11 /pmc/articles/PMC6739414/ /pubmed/31511657 http://dx.doi.org/10.1038/s41598-019-49533-y Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Abraham, Joseph R.
Szoko, Nicholas
Barnard, John
Rubin, Robert A.
Schlatzer, Daniela
Lundberg, Kathleen
Li, Xiaolin
Natowicz, Marvin R.
Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes
title Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes
title_full Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes
title_fullStr Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes
title_full_unstemmed Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes
title_short Proteomic Investigations of Autism Brain Identify Known and Novel Pathogenetic Processes
title_sort proteomic investigations of autism brain identify known and novel pathogenetic processes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739414/
https://www.ncbi.nlm.nih.gov/pubmed/31511657
http://dx.doi.org/10.1038/s41598-019-49533-y
work_keys_str_mv AT abrahamjosephr proteomicinvestigationsofautismbrainidentifyknownandnovelpathogeneticprocesses
AT szokonicholas proteomicinvestigationsofautismbrainidentifyknownandnovelpathogeneticprocesses
AT barnardjohn proteomicinvestigationsofautismbrainidentifyknownandnovelpathogeneticprocesses
AT rubinroberta proteomicinvestigationsofautismbrainidentifyknownandnovelpathogeneticprocesses
AT schlatzerdaniela proteomicinvestigationsofautismbrainidentifyknownandnovelpathogeneticprocesses
AT lundbergkathleen proteomicinvestigationsofautismbrainidentifyknownandnovelpathogeneticprocesses
AT lixiaolin proteomicinvestigationsofautismbrainidentifyknownandnovelpathogeneticprocesses
AT natowiczmarvinr proteomicinvestigationsofautismbrainidentifyknownandnovelpathogeneticprocesses